Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease
Parkinson’s disease (PD) is a widespread neurodegenerative disorder. Despite the intensive studies of this pathology, in general, the picture of the etiopathogenesis has still not been clarified fully. To understand better the mechanisms underlying the pathogenesis of PD, we analyzed the expression...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2015/294396 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552390251773952 |
|---|---|
| author | Anelya Kh. Alieva Elena V. Filatova Aleksey V. Karabanov Sergey N. Illarioshkin Petr A. Slominsky Maria I. Shadrina |
| author_facet | Anelya Kh. Alieva Elena V. Filatova Aleksey V. Karabanov Sergey N. Illarioshkin Petr A. Slominsky Maria I. Shadrina |
| author_sort | Anelya Kh. Alieva |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is a widespread neurodegenerative disorder. Despite the intensive studies of this pathology, in general, the picture of the etiopathogenesis has still not been clarified fully. To understand better the mechanisms underlying the pathogenesis of PD, we analyzed the expression of 10 genes in the peripheral blood of treated and untreated patients with PD. 35 untreated patients with PD and 12 treated patients with Parkinson’s disease (Hoehn and Yahr scores 1-2) were studied. An analysis of the mRNA levels of ATP13A2, PARK2, PARK7, PINK1, LRRK2, SNCA, ALDH1A1, PDHB, PPARGC1A, and ZNF746 genes in the peripheral blood of patients was carried out using reverse transcription followed by real-time PCR. A statistically significant and specific increase by more than 1.5-fold in the expression of the ATP13A2, PARK7, and ZNF746 genes was observed in patients with PD. Based on these results, it can be suggested that the upregulation of the mRNA levels of ATP13A2, PARK7, and ZNF746 in untreated patients in the earliest clinical stages can also be observed in the preclinical stages of PD, and that these genes can be considered as potential biomarkers of the preclinical stage of PD. |
| format | Article |
| id | doaj-art-ca469d9fbe4b42b0ab650a0c46e5de93 |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-ca469d9fbe4b42b0ab650a0c46e5de932025-02-03T05:58:46ZengWileyParkinson's Disease2090-80832042-00802015-01-01201510.1155/2015/294396294396Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s DiseaseAnelya Kh. Alieva0Elena V. Filatova1Aleksey V. Karabanov2Sergey N. Illarioshkin3Petr A. Slominsky4Maria I. Shadrina5Institute of Molecular Genetics, Russian Academy of Sciences, Moscow 123182, RussiaInstitute of Molecular Genetics, Russian Academy of Sciences, Moscow 123182, RussiaResearch Centre of Neurology, Moscow 125367, RussiaResearch Centre of Neurology, Moscow 125367, RussiaInstitute of Molecular Genetics, Russian Academy of Sciences, Moscow 123182, RussiaInstitute of Molecular Genetics, Russian Academy of Sciences, Moscow 123182, RussiaParkinson’s disease (PD) is a widespread neurodegenerative disorder. Despite the intensive studies of this pathology, in general, the picture of the etiopathogenesis has still not been clarified fully. To understand better the mechanisms underlying the pathogenesis of PD, we analyzed the expression of 10 genes in the peripheral blood of treated and untreated patients with PD. 35 untreated patients with PD and 12 treated patients with Parkinson’s disease (Hoehn and Yahr scores 1-2) were studied. An analysis of the mRNA levels of ATP13A2, PARK2, PARK7, PINK1, LRRK2, SNCA, ALDH1A1, PDHB, PPARGC1A, and ZNF746 genes in the peripheral blood of patients was carried out using reverse transcription followed by real-time PCR. A statistically significant and specific increase by more than 1.5-fold in the expression of the ATP13A2, PARK7, and ZNF746 genes was observed in patients with PD. Based on these results, it can be suggested that the upregulation of the mRNA levels of ATP13A2, PARK7, and ZNF746 in untreated patients in the earliest clinical stages can also be observed in the preclinical stages of PD, and that these genes can be considered as potential biomarkers of the preclinical stage of PD.http://dx.doi.org/10.1155/2015/294396 |
| spellingShingle | Anelya Kh. Alieva Elena V. Filatova Aleksey V. Karabanov Sergey N. Illarioshkin Petr A. Slominsky Maria I. Shadrina Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease Parkinson's Disease |
| title | Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease |
| title_full | Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease |
| title_fullStr | Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease |
| title_full_unstemmed | Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease |
| title_short | Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease |
| title_sort | potential biomarkers of the earliest clinical stages of parkinson s disease |
| url | http://dx.doi.org/10.1155/2015/294396 |
| work_keys_str_mv | AT anelyakhalieva potentialbiomarkersoftheearliestclinicalstagesofparkinsonsdisease AT elenavfilatova potentialbiomarkersoftheearliestclinicalstagesofparkinsonsdisease AT alekseyvkarabanov potentialbiomarkersoftheearliestclinicalstagesofparkinsonsdisease AT sergeynillarioshkin potentialbiomarkersoftheearliestclinicalstagesofparkinsonsdisease AT petraslominsky potentialbiomarkersoftheearliestclinicalstagesofparkinsonsdisease AT mariaishadrina potentialbiomarkersoftheearliestclinicalstagesofparkinsonsdisease |